Vancouver, British Columbia - Protox Therapeutics Inc. (TSX-V: PRX) announced today that it has filed a provisional patent application with the United States Patent and Trademark Office entitled “Modified Protein Toxins and Use Thereof for Treating Disease”. The patent application provides added protection for drug candidates generated through the PORxin™ platform whose binding sites are altered to target certain types of cells including cancer cells.
